TC
TScan Therapeutics, Inc.
TCRX · NASDAQ
$0.33 -2.28% (-$0.01)
1M -58.64%
Market Cap $20.2M
P/E Ratio -
Div. Yield -
ROE 108.72%
Bulios Fair Price
$0.49
48.2% upside
Current Price
$0.33
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TCRX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
81 /100
Cheap P/B 0.29x
P/S 2.84x
PEG N/A
Growth
14 /100
Declining Book val. growth 7.38%
Rev. growth 8.63%
FCF growth N/A
Profitability
20 /100
Weak FCF margin 1,665.57%
Op. margin 1,695.15%
Gross margin 90.25%
Quality
0 /100
Poor Asset turnover 0.04x
ROA 68.66%
ROIC 75.38%
Debt
42 /100
Moderate Current ratio 3.37x
Int. coverage -41.21x
Debt/Equity 1.32x
Stability
46 /100
Moderate Profitable years 0
EPS volatility 20.95%
Beta 1.07x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TCRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gavin MacBeath
Employees
138
Headquarters
Waltham
Upcoming events
11 NOV
Earnings
Upcoming earnings report